Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology,
inflammatory diseases, and, most particularly, oncology. Combined with the ability to …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality
of life (QoL). We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in …

1. MATERIALS AND METHODS Data regarding the diagnosis, management, and follow‐up
of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches …

The latest World Health Organization (WHO) classification from 2015 has grouped lung and
thymic neuroendocrine tumours (NETs)(named neoplasm in the digestive WHO …

Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic
neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade …

Introduction This document is a summary of the French Intergroup guidelines regarding the
management of digestive neuroendocrine neoplasms (NEN) published in February 2020 …

Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2
gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin …